Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 2Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Neoplasms by Site 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × patritumab × Clear all
NCT02633800 2019-01-07

Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )

Daiichi Sankyo

Phase 2 Terminated
87 enrolled 13 charts
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon âš¡